β3-adrenergic agonists: Potential therapeutics for obesity

Expert Opinion on Investigational Drugs

Volumn 6, Issue 12, 1997, Pages 1811-1825

  Dow, R L ^a  

^a PFIZER INC   (United States)

Author keywords

Agonist obesity; 3 adrenergic receptor

Indexed keywords

4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]ETHOXY]PHENYLACETIC ACID; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID; 4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID METHYL ESTER; 4 [2 [(2 HYDROXY 3 PHENOXYPROPYL)AMINO]ETHOXY] N (2 METHOXYETHYL)PHENOXYACETAMIDE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; 5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; AD 9677; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BMS 187257; BMS 187413; CP 114271; CP 209129; CP 331679; FR 149175; FR 165914; L 750355; L 755507; N [4 [2 [[2 HYDROXY 3 (4 HYDROXYPHENOXY)PROPYL]AMINO]ETHYL]PHENYL]BENZENESULFONAMIDE; UNCLASSIFIED DRUG;

HUMAN; OBESITY; REVIEW;

EID: 0030679641     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.6.12.1811     Document Type: Review

References (126)